Abstract

BackgroundA subset of patients with ductal carcinoma in situ (DCIS) will develop invasive breast cancer (IBC). To date, there are no effective predictive biomarkers for identifying this subset with worse prognosis whose lesions are essentially indistinguishable histologically from those with favorable outcomes. We hypothesized that measurable parameters that discriminate DCIS from DCIS with concurrent invasion may serve as diagnostic biomarkers (BM) of progressive cancer in situ (CIS).ResultsUsing a novel imaging-based method of tissue testing, we measured the relative expression levels of three candidate BM proteins specifically implicated in IBC progression - the insulin-like growth factor I receptor (IGF-IR), Ras-related protein 1 (Rap1), and Vav2 oncoprotein. Protein profiles were compared in 42 histologically normal mammary epithelial samples, 71 CIS (35 without/36 with invasion either on diagnostic biopsy or final surgical excision), and 98 IBC of known estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. The levels of the IGF-IR and Rap1 protein expression were significantly elevated in ER-positive (ER+/PR+/-/HER2 –) DCIS relative to normal epithelium (P <0.0001). The IGF-IR protein expression was also significantly up regulated in HER2-positive (ER+/-/PR+/-/HER2+) DCIS relative to normal epithelium (P = 0.0002). IGF-IR and Rap1 protein expression levels were similar among DCIS patients without or with concurrent invasion. Vav2 upregulation in DCIS relative to normal group was not associated with steroid hormone receptor and HER2 status, but was associated with the presence of concurrent invasion, including microinvasion (invasive foci of less than 1 mm). DCIS with high Vav2 were more than twice as likely to progress to invasive cancers as DCIS with low Vav2 (odds ratio, 2.42; 95% CI, 1.26-4-65; P =0.008). Furthermore, a receiver operating characteristic curve analysis revealed moderate ability of Vav2 protein expression measurements in DCIS to predict the existence of invasion concurrent with DCIS (area under the curve, 0.71; 95% CI, 0.59- 0.84).ConclusionsOur novel findings hold promise for utilizing Vav2 protein as a predictive BM for differentiating progressive from non-progressive DCIS.Electronic supplementary materialThe online version of this article (doi:10.1186/2050-7771-2-22) contains supplementary material, which is available to authorized users.

Highlights

  • A subset of patients with ductal carcinoma in situ (DCIS) will develop invasive breast cancer (IBC)

  • Higher levels of insulin-like growth factor I receptor (IGF-IR) were expressed in the cancer in situ (CIS) group than in the normal group (P

  • related protein 1 (Rap1) protein expression was significantly upregulated in the CIS group compared to the normal group (P

Read more

Summary

Introduction

A subset of patients with ductal carcinoma in situ (DCIS) will develop invasive breast cancer (IBC). Ductal carcinoma in situ (DCIS) of the breast is a noninvasive lesion most commonly detected in asymptomatic women as a small area of abnormal calcification on mammography. Little is known about molecular biomarkers (BM) that may help to determine the likelihood that DCIS identified on diagnostic biopsy would remain contained in situ or become invasive [3]. Our candidate BMs, the insulin-like growth factor I receptor (IGF-IR), Ras-related protein 1 (Rap1), and oncoprotein Vav, are molecules whose upregulation have been implicated in promoting the aggressive behavior of cancer cells in preclinical models [4,5,6]. We hypothesized that up-regulation of IGF-IR/Rap may increase the propensity of DCIS transitioning to IBC

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.